(Q35879814)

10 August 2017

6 references

3 April 2019

25 June 2019

19 September 2019

1 September 2020

13 November 2020

8 February 2021

Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies? (English)

1 reference

biomedical investigative technique

10 August 2017

1 reference

3 April 2019

1 reference

19 September 2019

1 reference

1 September 2020

1 reference

13 November 2020

1 reference

8 February 2021

N Tunariu

1

1 reference

10 August 2017

S B Kaye

series ordinal

2

1 reference

10 August 2017

N M Desouza

series ordinal

3

1 reference

10 August 2017

language of work or name

English

0 references

publication date

26 January 2012

1 reference

British Journal of Cancer

10 August 2017

14 February 2012

6 references

3 April 2019

25 June 2019

19 September 2019

1 September 2020

13 November 2020

8 February 2021

7 references

10 August 2017

3 April 2019

25 June 2019

19 September 2019

1 September 2020

13 November 2020

8 February 2021

106

1 reference

10 August 2017

4

1 reference

10 August 2017

619-628

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2011.579

10 August 2017

0 references

cites work

Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Advances in MRI assessment of gliomas and response to anti-VEGF therapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results 1

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Multimodality tumor imaging targeting integrin alphavbeta3.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Reproducibility of serial whole-brain MR spectroscopic imaging

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Molecular imaging of hypoxia with radiolabelled agents

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

The parametric response map is an imaging biomarker for early cancer treatment outcome

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Imaging of HER-2 overexpression in tumors for guiding therapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Imaging oxygenation of human tumours

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Can the pharmaceutical industry reduce attrition rates?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

11 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Reproducibility of tumor perfusion measurements using 15O-labeled water and PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Perfusion estimated with rapid dynamic contrast-enhanced magnetic resonance imaging correlates inversely with vascular endothelial growth factor expression and pimonidazole staining in head-and-neck cancer: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Quantitative assessment of tissue perfusion using MDCT: comparison of colorectal cancer and skeletal muscle measurement reproducibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation O

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Early evaluation of cancer response by a new functional biomarker: apparent diffusion coefficient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.579

18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322943

Assessing response in bone metastases in prostate cancer with diffusion weighted MRI

24 September 2018

1 reference

12 December 2020

Quantitative Parametric Perfusion Images Using 15O-Labeled Water and a Clinical PET/CT Scanner: Test-Retest Variability in Lung Cancer

1 reference

12 December 2020

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

1 reference

12 December 2020

To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2011.579

1 reference

release_ngdl2fbpc5hlvarpgywtutroke

10 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ngdl2fbpc5hlvarpgywtutroke

24 November 2022

mapped directly with Wikidata item

1 reference

10 August 2017

1 reference